Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19

Zhuang, Zhenjie; Zhong, Xiaoying; Chen, Qianying; Chen, Huiqi; Liu, Zhanhua

doi:10.3389/fphar.2022.857730

Cited by 4 publications

(3 citation statements)

References 213 publications

(202 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have previously highlighted the role of p53 in SARS-CoV-2 infection [ 34 , 35 ], pointing out p53 as a potential target for the development of antivirals [ 36 , 37 ]. In contrast, our data show that the increase in SARS-CoV-2 replication observed when the cells are stopped in G1 is p53-independent, making the use of p53 targeting antivirals ineffective in this case.…”

Section: Discussionmentioning

confidence: 99%

P53-Independent G1-Cell Cycle Arrest Increases SARS-CoV-2 RNA Replication

Husser,

Kwon,

Andersson

et al. 2024

Microorganisms

View full text Add to dashboard Cite

While having already killed more than 7 million of people worldwide in 4 years, SARS-CoV-2, the etiological agent of COVID-19, is still circulating and evolving. Understanding the pathogenesis of the virus is of capital importance. It was shown that in vitro and in vivo infection with SARS-CoV-2 can lead to cell cycle arrest but the effect of the cell cycle arrest on the virus infection and the associated mechanisms are still unclear. By stopping cells in the G1 phase as well as targeting several pathways involved using inhibitors and small interfering RNAs, we were able to determine that the cell cycle arrest in the late G1 is beneficial for SARS-CoV-2 replication. This cell cycle arrest is independent of p53 but is dependent on the CDC25A-CDK2/cyclin E pathway. These data give a new understanding in SARS-CoV-2 pathogenesis and highlight some possible targets for the development of novel therapeutic approaches.

show abstract

Section: Discussionmentioning

confidence: 99%

P53-Independent G1-Cell Cycle Arrest Increases SARS-CoV-2 RNA Replication

Husser,

Kwon,

Andersson

et al. 2024

Microorganisms

View full text Add to dashboard Cite

show abstract

“…The study increased the pathophysiological understanding of COVID-19 and NSCLC. 111 Upon investigating the clinical management of NSCLC patients during the first wave of COVID-19, it was found that a considerably diminished diagnosis of lung cancer cases was being done. Telemedicine helped in patienthealthcare interactions and in administering concurrent therapeutic regimes for managing lung cancer patients with COVID.…”

Section: Lung Cancermentioning

confidence: 99%

“…The enrichment analysis revealed common signaling pathways between COVID‐19 and NSCLC. The study increased the pathophysiological understanding of COVID‐19 and NSCLC 111 . Upon investigating the clinical management of NSCLC patients during the first wave of COVID‐19, it was found that a considerably diminished diagnosis of lung cancer cases was being done.…”

Section: Unveiling the Lethal Convergence: Exploring The Intersection...mentioning

confidence: 99%

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Ghosh,

Tabassum,

Basu

2023

MedComm – Oncology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic brought about unprecedented challenges to global healthcare systems. Among the most vulnerable populations are cancer patients, who face dilemmas due to their compromised immune systems and the intricate interplay with the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus. This comprehensive review delves into the multifaceted relationship between COVID‐19 and cancer. Through an analysis of existing literature and clinical data, this review unravels the structural intricacies of the virus and examines its profound implications for cancer patients, thereby bridging the knowledge gap between virology and oncology. The review commences with an introduction regarding the COVID‐19 pandemic and cancer. It then transitions into a detailed examination of the SARS‐CoV‐2 virus and its variants such as Alpha (PANGO lineage B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529 lineage). Subsequently, an insightful analysis of the impact of COVID‐19 on major cancer types (viz., Lung, Colon, Brain, and gastrointestinal cancer) is elaborated. Finally, the therapeutic avenues, oncological care, and management are discussed. The nexus between COVID‐19 and cancer adds a layer of complexity to patient care, emphasizing the importance of tailored approaches for those grappling with both conditions. Amid the landscape defined by the evolving viral strains, this review navigates through the multifaceted implications of COVID‐19 on cancer patients and underscores the significance of integrating virology and oncology.

show abstract